AHSG
Alpha-2-HS-glycoprotein
Also known as: A2HS, FETUA, FETUA_HUMAN, HSGA
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P02765
- Gene
- AHSG
- Ensembl
- ENSG00000145192
- Chromosome
- 3
- Canonical length
- 367 aa
- Protein class
- Cancer-related genes, Disease related genes, Human disease related genes, Plasma proteins, Predicted secreted proteins
- Subcellular location
- Golgi apparatus
- Secretome location
- Secreted to blood
OverviewNCBI Gene
The protein encoded by this gene is a negatively-charged serum glycoprotein that is synthesized by hepatocytes. The encoded protein consists of two polypeptide chains, which are both cleaved from a proprotein encoded from a single mRNA. It is involved in several processes, including endocytosis, brain development, and the formation of bone tissue. Defects in this gene are a cause of susceptibility to leanness. [provided by RefSeq, Aug 2017]
Canonical amino-acid sequenceUniProt
367 residues, UniProt reviewed canonical sequence.
>P02765|AHSG
1 MKSLVLLLCL AQLWGCHSAP HGPGLIYRQP NCDDPETEEA ALVAIDYINQ NLPWGYKHTL
61 NQIDEVKVWP QQPSGELFEI EIDTLETTCH VLDPTPVARC SVRQLKEHAV EGDCDFQLLK
121 LDGKFSVVYA KCDSSPDSAE DVRKVCQDCP LLAPLNDTRV VHAAKAALAA FNAQNNGSNF
181 QLEEISRAQL VPLPPSTYVE FTVSGTDCVA KEATEAAKCN LLAEKQYGFC KATLSEKLGG
241 AEVAVTCMVF QTQPVSSQPQ PEGANEAVPT PVVDPDAPPS PPLGAPGLPP AGSPPDSHVL
301 LAAPPGHQLH RAHYDLRHTF MGVVSLGSPS GEVSHPRKTR TVVQPSVGAA AGPVVPPCPG
361 RIRHFKVLocalizationUniProt · AlphaFold · HPA
Whether an antibody against AHSG can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.41
- Highest tissue expression
- 5,440 nTPM
Expression across tissuesHPA
Tissue
- liver: 5,440 nTPM
- kidney: 1.2 nTPM
- pancreas: 1.2 nTPM
- testis: 1.1 nTPM
- spleen: 0.8 nTPM
- adipose tissue: 0.2 nTPM
Single-cell type
- hepatocytes: 1,253 nCPM
- late spermatids: 92 nCPM
- early spermatids: 87 nCPM
- kupffer cells: 14 nCPM
- hepatic stellate cells: 13 nCPM
- cholangiocytes: 7.2 nCPM
Immune cell
- NK-cell: 0.1 nTPM
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
Brain region
- cerebral cortex: 0.3 nTPM
- white matter: 0.2 nTPM
- amygdala: 0.1 nTPM
- basal ganglia: 0.1 nTPM
- hippocampal formation: 0.1 nTPM
- hypothalamus: 0.1 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about AHSG.
Disease | AllUniProt
Conditions AHSG is implicated in, by any mechanism.
- Alopecia-intellectual disability syndrome 1 (APMR1) MIM:203650
Disease | GeneticClinVar
1 pathogenic / likely-pathogenic of 80 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Alopecia-intellectual disability syndrome 1
ReferencesPubMed · IEDB
Publications for AHSG from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
2 publications
- Autoantibody to tumor antigen, alpha 2-HS glycoprotein: a novel biomarker of breast cancer screening and diagnosis.
2009 · Cancer Epidemiol Biomarkers Prev · RCR 1.6 · 53 citations - Alpha 2HS-glycoprotein, a tumor-associated antigen (TAA) detected in Mexican patients with early-stage breast cancer.
2015 · J Proteomics · RCR 0.7 · 17 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.66
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.36
- DepMap mean gene effect
- -0.01
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- acute-phase response
- negative regulation of bone mineralization
- negative regulation of insulin receptor signaling pathway
- ossification
- pinocytosis
- positive regulation of phagocytosis
- regulation of bone mineralization
- regulation of inflammatory response
- skeletal system development
Molecular functions
- cysteine-type endopeptidase inhibitor activity
- endopeptidase inhibitor activity
- kinase inhibitor activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads AHSG as an antibody target. Whether an autoantibody or antibody against AHSG could matter depends on whether native AHSG is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
AHSG is annotated as secreted, so native AHSG circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label AHSG as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...